Cargando…

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145730/ http://dx.doi.org/10.2147/OTT.S70489

Ejemplares similares

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
por: Lyon, Kristopher A., et al.
Publicado: (2020)

Corrigendum to “Cell therapies in ovarian cancer”
Publicado: (2021)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Chemotherapy Induces Ovarian Cancer Cell Repopulation Through the Caspase 3-Mediated Arachidonic Acid Metabolic Pathway [Corrigendum]
Publicado: (2022)

Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel [Corrigendum]
Publicado: (2023)

Corrigendum to “Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients”
por: Zhang, Jue, et al.
Publicado: (2021)

Corrigendum to “Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy”
por: Moastafa, Tarek M., et al.
Publicado: (2015)

The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy [Corrigendum]
Publicado: (2019)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Corrigendum to “Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis”
Publicado: (2020)

Upregulated LINC00565 Accelerates Ovarian Cancer Progression by Targeting GAS6 [Corrigendum]
Publicado: (2020)

Corrigendum: Interspecific comparison of sensitivity to paralytic compounds
Publicado: (2020)

Efficient Inhibition of Ovarian Cancer by Degradable Nanoparticle-Delivered Survivin T34A Gene [Corrigendum]
Publicado: (2020)

Corrigendum to: Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India
por: Sharma-Oates, Archana, et al.
Publicado: (2018)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Albumin-Encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo [Corrigendum]
Publicado: (2023)

Corrigendum to “Comparative Sensitivity Analysis of Muscle Activation Dynamics”
por: Rockenfeller, Robert, et al.
Publicado: (2017)

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2023)

Corrigendum to: EGFR mediates LPA‐induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol
Publicado: (2019)

Circulating Serum Exosomal aHIF Is A Novel Prognostic Predictor For Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2019)

Effects of Adenosine on Apoptosis of Ovarian Cancer A2780 Cells via ROS and Caspase Pathways [Corrigendum]
Publicado: (2020)

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Corrigendum to “Polarity Sensitivity in Pediatric and Adult Cochlear Implant Listeners”
Publicado: (2020)

Corrigendum to: Limited evolutionary conservation of multidrug resistance and collateral sensitivity
por: Apjok, Gábor, et al.
Publicado: (2021)

Corrigendum to “The Protective Effect of N-Acetylcysteine on Ionizing Radiation Induced Ovarian Failure and Loss of Ovarian Reserve in Female Mouse”
por: Gao, Wei, et al.
Publicado: (2021)

Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review [Corrigendum]
Publicado: (2023)

Corrigendum to: “Role of Ovarian Hormones in the Modulation of Sleep in Females Across the Adult Lifespan”
Publicado: (2021)

Corrigendum to: Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study
por: Fatayer, Hiba, et al.
Publicado: (2022)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
Publicado: (2019)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

Corrigendum: Effect of Dandelion Extracts on the Proliferation of Ovarian Granulosa Cells and Expression of Hormone Receptors
Publicado: (2018)

Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Publicado: (2023)

Corrigendum to “miR-486 Promotes the Invasion and Cell Cycle Progression of Ovarian Cancer Cells by Targeting CADM1”
por: Wang, Hao, et al.
Publicado: (2021)

[Corrigendum] miR‑1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer
por: Pei, Yuqing, et al.
Publicado: (2023)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1gpbu1lcus13053bmo4asnete5